At the 2019 American Society of Health-System Pharmacists Midyear Clinical Meeting in Las Vegas, the educators reviewed the 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed. The Multiple Risk Factor Intervention Trial (MRFIT) and the Multiple Risk Factor Intervention Trial II (MRFIT II) were reassessed and determined as being adequately reflected in the 2017 ACC/AHA High Blood Pressure Guidelines with respect to the outcomes of four major trials discussed.

The eighth Joint National Committee (JNC 8) are the 2014 evidence-based guidelines for the management of high blood pressure with nine recommendations addressing three questions: Which medications are best? How should blood pressure be lowered for those undergoing treatment? Which medications are best for a patient’s (19) years old with hypertension? (20)

The ACC/AHA Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (21) guidelines are comprehensive, succinct, and practical. They review new data on an ongoing basis, are based on widespread and a full guideline revision is commissioned in approximately six-year cycles. Hence, it is recommended to follow the 2017 ACC/AHA High Blood Pressure Guidelines

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.

The 2017 ACC/AHA Hypertension Guidelines with respect to the outcomes of four major trials discussed.
Advise all patients of the risk of neuropsychiatric events when prescribing montelukast. Warnings about these side effects are included in the existing typing and matching. Current FDA labeling recommends individualized dosing ranging from 25 to 50 units/kg of factor IX, based on patient body weight, however, this regimen was not based on dose-finding studies. Previous studies in the United States and abroad have attempted to determine an optimal fixed dose regimen of KCentra. However, a four-folder prothrombin complex concentrate (4F-PCC) and is indicated for reversal of major bleeding in adults hospitalized with CAP. Generally, the study found that the association between CAP and PCT correction followed historic evidence. However, the study found that the mean PCT value of atypical bacteria was 0.20 ng/mL, which would generally indicate an unlikely bacterial infection according to a PCT algorithm. The study concluded that the PCT threshold allowed for perfect become elevated during viral infections. Due to its ability to differentiate between viral and bacterial pathogens, the PCT assay has been Food and Drug Administration (FDA)-approved for use in less respiratory tract infections (URTs) and sepsis. PCT may be used in LRTrs to determine infection or discontinuation of antibiotic therapy. According to common PCT algorithms, if a PCT level is >0.25 ng/mL, a bacterial infection is considered unlikely and antibiotics should not be initiated, and if a PCT level is <0.25 ng/mL, a bacterial infection is considered likely and antibiotics should be initiated. In 2017, Seif et al. published a multicenter surveillance study to evaluate the association between serum PCT concentration with pathogens detected in adults hospitalized with CAP. Generally, the study found that the association between CAP and PCT correction followed historic evidence. However, the study found that the mean PCT value of atypical bacteria was 0.20 ng/mL, which would generally indicate an unlikely bacterial infection according to a PCT algorithm. The study concluded that the PCT threshold allowed for perfect discrimination between viral and bacterial detection, and clinicians could not rely on PCT alone to guide antibiotic treatment decisions. However, this study was limited due to the lack of rechecking PCT level, the low percentage of patients who presented with atypical bacteria (4%), and the large percentage of patients who did not have pathogens detected at all (62%). In 2018, Huang et al. published the ProACT trial to assess whether a PCT-guided antibiotic treatment algorithm would result in less exposure to antibiotics than usual care in patients with acute LRTI without a significantly higher rate of mortality. The study did not find any statistically significant differences between the two groups, and concluded that a PCT-guided approach did not show any clinically improved outcomes compared to standard of care. However, this study was largely limited to the number of CAP patients included (20%) and lack of clinical adherence to the study protocol. Ultimately, the most recent studies discrediting PCT are not strong enough to rule out its use for initiation of antibiotics in CAP, and more evidence and well-constructed studies are required before PCT can be ruled out as a useful biomarker in determining whether to initiate antibiotics in patients with lower severity CAP.

The American Thoracic Society and the Infectious Diseases Society of America (IDSA) have recommended antibiotic guidance for community-acquired pneumonia (CAP). While the role of viral pathogens is acknowledged, the guideline recommends initial empiric treatment for bacterial pathogens. Several important changes from the 2007 recommendations for inpatient treatment should be noted:

- The mainstay of non-severe, inpatient CAP remains as combination therapy, which includes a β-lactam (ceftriaxone or amoxicillin/sulbactam) and a macrolide (azithromycin or clarithromycin) or a β-lactam and doxycycline are acceptable alternatives for patients whose macrolides or fluoroquinolones are contraindicated. For severe CAP, both a β-lactam/macrolide combination is preferred over monotherapy. A β-lactam and doxycycline combination is not recommended in patients with high creatinine clearance due to the potential for severe adverse effects as well as a possible mortality benefit exists for β-lactam/macrolide combination. In addition, the health-care associated pneumonia (HCAP) designation is discouraged, and considering risk factors for methicillin-resistant staphylococcus aureus (MRSA) and pseudomonas is recommended.

Empiric coverage for MRSA should be added for all patients with a history of MRSA infection or for patients with severe pneumonia and a hospitalization which included IV antibiotics in the last 90 days. Similarly, empiric anti-pseudomonas coverage is indicated for all patients with a history of pneumonias in fection and patients with severe disease and hospitalization with IV antibiotics in the last 90 days. In cases of non-severe disease and recent hospitalization with IV antibiotics, cultures should be obtained and anti-MRSA or anti-pseudomonal treatment initiated if cultures are positive. Blood and sputum cultures are not recommended in all patients with a severe disease and any patient who is being treated empirically for MRSA or pseudomonas.

Anecoretic coverage is not recommended unless lung abscess or empyema is suspected. Aspiration pneumonitis following aspiration of gastric contents is expected to resolve in 24-48 hours with supportive treatment alone. In order to minimize the emergence of resistant organisms, de-escalation should occur as soon as possible. If MRSA rapid nasal polymerase chain reaction (PCR) is negative, MRSA pneumonia is unlikely and coverage can be discontinued. Negative culture results may also be used to de-escalate anti- biotic coverage. While procalcitonin is not recommended for determining the need for initial therapy, serial levels may be useful in reducing duration, when the usual length of treatment (5-7 days) is exceeded. A five-day duration is sufficient if the patient has achieved clinical stability (resolution of vital abnormalities including heart rate, respiratory rate, blood pressure, oxygen saturation, temperature and normal mentation).

LBH Empiric Antibiotic Guidelines are being updated to reflect the new CAP guidelines. While amoxicillin/sulbactam is included in the Empiric Guidelines, it is currently restricted due to limited availability.